Jade Biosciences to Participate in Several Industry Conferences
News provided byJade Biosciences, Inc · 1 min read
San Francisco and Vancouver, British Columbia, September 1, 2026, Jade Biosciences, Inc. (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases, will participate in several upcoming industry conferences, providing insights into its pipeline and strategic initiatives.
The company will host fireside chats and one-on-one investor meetings at the following events: - Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, at 3:45 p.m. ET - Citi 2026 Biopharma Back to School Summit on Wednesday, September 9, at 9:20 a.m. ET - H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, at 1:00 p.m. ET - Stifel Virtual Immunology and Inflammation Forum on Wednesday, September 23, at 10:30 a.m. ET
Members of Jade Biosciences’ management team will be present to discuss the company’s latest developments and answer questions from attendees. Live webcasts of the fireside chats from Wells Fargo, Citi, and H.C. Wainwright will be available on the company’s website, with archived replays accessible for 90 days following the events.
Jade Biosciences, founded on assets licensed from Paragon Therapeutics, an antibody discovery engine established by Fairmount, is dedicated to advancing best-in-class therapies for autoimmune diseases. The company’s lead candidate, JADE101, is designed to target the cytokine APRIL and is currently being evaluated for the treatment of immunoglobulin A nephropathy. The pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an anti-IFN-β monoclonal antibody.
Shah added, “Our management team looks forward to discussing our strategies and pipeline with attendees, and we are committed to keeping our investors informed about our progress and future plans.”
Jade Biosciences’ commitment to developing cutting-edge treatments for autoimmune diseases is underscored by its ongoing clinical trials and strategic partnerships. While the company remains optimistic about its product candidates, it also acknowledges the inherent risks and uncertainties associated with the development process.
Investors and stakeholders can find more information about Jade Biosciences on the company’s website and through its LinkedIn page.